10 resultaten
The Ticlopidine Microangiopathy of Diabetes study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years.
Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years. However, long-term safety of OCT has not been documented in placebo-controlled setting. This present analysis pooled safety data from two similarly-designed, randomized, and
A 60-year-old man with neovascular glaucoma due to diabetic retinopathy received an intravitreal injection of 1.25 mg bevacizumab (IVB) followed by extensive panretinal photocoagulation in the right eye. The anterior segment neovascularization regressed within 10 days after IVB. One and a half
INTRODUCTION
Diabetic peripheral neuropathic pain (DPNP) affects the functionality, mood, and sleep patterns of patients with diabetes. Mirogabalin, an α
2 δ ligand with a slower dissociation for α
2 δ-1 vs α
2 δ-2 subunits, demonstrated efficacy and
Growth hormone is assumed to be involved in the development of diabetic retinopathy. In a randomized study we evaluated the possible effects of one year treatment with a somatostatin (SRIH) analogue, octreotide, on early retinopathy and on metabolism in Type I (insulin-dependent) diabetes mellitus.
OBJECTIVE
To investigate the potential of lipoprotein-associated phospholipase A2 inhibition as a novel mechanism to reduce edema and improve vision in center-involved diabetic macular edema (DME).
METHODS
Prospective, multicenter, randomized, double-masked, placebo-controlled phase IIa
Background
Pueraria
lobata is used in traditional Asian medicine to treat cardiovascular diseases,
diarrhea, diabetes mellitus, and diabetic complications such as
diabetic retinopathy. Oxidative stress in retinal pigment epithelial cells is implicated in the pathogenesis
To assess the efficacy and safety of oral semaglutide, a novel glucagon-like peptide 1 receptor agonist, for patients with type 2 diabetes mellitus.METHODS
We searched Medline, Embase, the Cochrane Library, and grey literature sources up to July
At the present time only two long-acting somatostatin (SS) analogs, octreotide and lanreotide, are commonly used in the routine therapy. Both analogs have a high affinity mainly to a somatostatin receptor subtype 2 (SSTR2). The established indications for SS analogs treatment include acromegaly,
Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to